Vertex Pharmaceuticals has two clinical-stage programs for type 1 diabetes, each employing different methods for preventing the immune system from rejecting the cell therapies. For a third program in ...

-Vertex to receive non-exclusive rights to CRISPR Therapeutics’ CRISPR/Cas9 to accelerate development of potentially curative cell therapies for T1D- BOSTON & ZUG, Switzerland--(BUSINESS WIRE)--Vertex ...

CRISPR Therapeutics (NASDAQ:CRSP) said Monday that Vertex Pharmaceuticals (VRTX) subsidiary ViaCyte has elected to opt-out of their development partnership for gene-edited stem cell therapies for the ...

CRISPR Therapeutics CRSP, along with partner ViaCyte, announced that Health Canada has approved the clinical trial application for its investigational allogeneic stem cell-derived therapy, VCTX210.

Vertex Pharmaceuticals said today it has agreed to acquire ViaCyte for $320 million cash, in a deal that bolsters the buyer’s diabetes pipeline with ViaCyte’s triple-pronged attack against the disease ...

Vertex Therapeutics VRTX announced that it is entering into a new non-exclusive licensing agreement with CRISPR Therapeutics CRSP for the use of the latter’s gene-editing technology, CRISPR/Cas9. The ...

A potential cure for type 1 diabetes has been identified by scientists in a new mouse study.In an animal study, researchers ...

Who invented CRISPR 2.0? What happens when a drug company actually lowers prices? And is Novavax going to survive? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast.

Shares of Crispr Therapeutics gained 3.1% in premarket trading on Wednesday after the company said the first patient had been dosed in a Phase 1 clinical trial evaluating the experimental type 1 ...

-Vertex to receive non-exclusive rights to CRISPR Therapeutics' CRISPR/Cas9 to accelerate development of potentially curative cell therapies for T1D- -CRISPR Therapeutics to receive $100M upfront ...